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AbsTrACT
Objective Calgranulin-C (S100A12) is a new faecal 
marker of inflammation that is potentially more specific 
for inflammatory bowel disease (IBD) than calprotectin, 
since it is only released by activated granulocytes. We 
compared calgranulin-C and calprotectin to see which of 
the two tests best predicted IBD in children with chronic 
abdominal pain and diarrhoea.
Design Delayed-type cross-sectional diagnostic study.
setting and patients Previously undiagnosed patients 
aged 6–17 years, who were seen in paediatric clinics in 
the Netherlands and Belgium, sent in a stool sample for 
analysis. Patients with a high likelihood of IBD underwent 
upper and lower endoscopy (ie, preferred reference test), 
while those with a low likelihood were followed for 
6 months for latent IBD to become visible (ie, alternative 
reference test). We used Bayesian modelling to correct 
for differential verification bias.
Main outcome measures Primary outcome was 
the specificity for IBD using predefined test thresholds 
(calgranulin-C: 0.75 µg/g, calprotectin: 50 µg/g). 
Secondary outcome was the test accuracy with 
thresholds based on receiver operating characteristics 
(ROC) analysis.
results IBD was diagnosed in 93 of 337 patients. 
Calgranulin-C had significantly better specificity than 
calprotectin when predefined thresholds were used 
(97% (95% credible interval (CI) 94% to 99%) vs 71% 
(95% CI 63% to 79%), respectively). When ROC-
based thresholds were used (calgranulin-C: 0.75 µg/g, 
calprotectin: 400 µg/g), both tests performed equally well 
(specificity: 97% (95% CI 94% to 99%) vs 98% (95% CI 
95% to 100%)).
Conclusions Both calgranulin-C and calprotectin have 
excellent test characteristics to predict IBD and justify 
endoscopy.
Trial registration number NCT02197780.
InTrODuCTIOn
Inflammatory bowel diseases (IBDs), including 
Crohn’s disease and ulcerative colitis, are lifelong 
conditions that often begin in childhood. Suspicion 
is raised in children and teenagers with chronic 
abdominal pain and diarrhoea. Additional red 
flag symptoms including rectal bleeding, weight 
loss and anaemia increase the suspicion of the 
condition. Endoscopic evaluation of the upper 
and lower gastrointestinal tract with biopsies 
for histology is essential to diagnose IBD and to 
differentiate Crohn’s disease from ulcerative colitis 
and IBD unclassified, start appropriate therapy and 
prevent progressive bowel damage.1 Many children 
consider endoscopy and the required bowel prepa-
ration to be uncomfortable.2 Identification of chil-
dren with a low likelihood of IBD would justify a 
non-invasive ‘watchful waiting’ strategy, while iden-
tification of those with a sufficiently high likelihood 
of IBD would justify urgent referral to specialist 
services for endoscopy.
In recent years, the stool calprotectin test has 
been promoted as a safe and easy interpretable 
triage tool for endoscopy.3 4 Calprotectin is mainly 
released by neutrophil granulocytes, but other 
cells including monocytes and epithelial cells do 
also excrete this protein.5 To date, a calprotectin 
concentration below 50 µg/g has been proposed to 
rule out IBD and not to proceed to endoscopy.6 7 
However, there are concerns about the mediocre 
specificity of the test at this threshold, which may 
What is already known on this topic?
 ► The calprotectin stool test has been promoted 
as a non-invasive and easy interpretable triage 
tool to predict inflammatory bowel disease 
(IBD) in children.
 ► A calprotectin concentration below 50 µg/g 
has been proposed to rule out IBD and not to 
proceed to endoscopy.
 ► When this threshold is used, a considerable 
proportion of children and teenagers with 
chronic abdominal pain and diarrhoea are 
exposed to a pointless invasive procedure.
What this study adds?
 ► This large-scale diagnostic study in a real-life 
cohort of children with chronic abdominal pain 
and diarrhoea shows that the new calgranulin-C 
stool test has significantly better specificity than 
calprotectin.
 ► When the calprotectin stool test is used, a 
two-threshold strategy is recommended with 
concentrations below 50 µg/g to rule out IBD 
and concentrations above 400 µg/g to rule in 
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give rise to a considerable proportion of children and teenagers 
proceeding to a pointless invasive procedure.
Calgranulin-C (S100A12) is a less frequently investigated 
marker of intestinal inflammation that is almost exclusively 
released by activated granulocytes.5 In previous case–control 
studies, calgranulin-C showed diagnostic promise with better 
specificity compared with calprotectin,8–10 but large studies in a 
prospective cohort with chronic abdominal pain and diarrhoea 
are lacking.
The aim of this study was to compare calprotectin and 
calgranulin-C to see which of the two markers best predicted 




This was an international multicentre, delayed-type, cross-sec-
tional diagnostic accuracy study with a paired design.11 Previ-
ously undiagnosed children and teenagers presenting with 
persistent diarrhoea for more than 4 weeks or chronic or recur-
rent abdominal pain were screened with the calprotectin stool 
test (existing test) and with the calgranulin-C test (new test). 
Confirmation of the target condition (IBD) was based on endos-
copy with biopsies (reference standard) or clinical follow-up 
(alternative reference standard). The study was registered before 
recruitment of the first participant, and the study protocol has 
been published in BMJ Open.12
Patients
Patients were recruited from 16 secondary and 3 tertiary level 
hospitals in the Netherlands and Belgium. They were eligible 
when aged between 6 years and 17 years. The flow of patients 
from the first hospital visit to the choice of the reference test was 
described comprehensively in our published study protocol.12 
In brief, during the first hospital visit, baseline characteristics, 
date of birth, presence of major and minor red flag signs and 
symptoms for IBD and use of non-steroidal anti-inflammatory 
drugs were entered on the study website (www. cacatustudie. 
eu). A stool specimen was collected at home and sent to the 
hospital laboratory of the coordinating study centre, where it 
was immediately tested for calprotectin and colon pathogens 
(including Shigatoxin-producing Escherichia coli, Salmonella, 
Shigella, Enteroinvasive E. coli, Campylobacter and Giardia 
lamblia) with a real-time multiplex PCR technique. Residual 
faeces was stored at −80°C for calgranulin-C batch testing at 
a later stage.
Assays
Stool calprotectin concentrations (μg/g) were measured with the 
fCAL ELISA (BÜHLMANN Laboratories AG, Schönenbuch, 
Switzerland) and stool calgranulin-C concentrations (μg/g) with 
the commercially available Inflamark ELISA (CisBio Bioassays, 
Codolet, France), both on a Dynex DS2 Automated ELISA 
System (Alpha Labs, Easleigh, UK) in the same laboratory. The 
extraction and measuring technique of calgranulin-C was previ-
ously described in detail.13 In discordant pairs (ie, increased 
calprotectin and normal calgranulin-C, or vice versa), we did a 
post hoc analysis of potential viral causes (adeno, entero, astro, 
rota, noro, parecho and sapovirus). Laboratory technicians were 
blinded for symptoms filled in on the website. The attending 
paediatricians were informed of the calprotectin and PCR 
result for bacteria and G. lamblia, but they were blinded for 
the calgranulin-C and PCR result for viruses. The predefined 
thresholds used in this study were 50 µg/g for calprotectin and 
0.75 µg/g for calgranulin-C.
reference tests
We used an automated IBD Risk Stratifier (figure 1) to advice 
paediatricians whether patients should proceed to endoscopy 
(the preferred reference standard) for verification of IBD, 
or whether they should be followed up clinically for possible 
latent IBD to become visible (the alternative reference standard). 
Paediatricians could deviate from this advice for documented 
clinical reasons. Endoscopy was performed under general anaes-
thesia by an experienced paediatric gastroenterologist in one of 
six participating centres. Both upper and lower gastrointestinal 
tracts were evaluated according to the revised Porto criteria,14 
and biopsies were taken from every bowel segment. Histopatho-
logical examination was performed by experienced histopathol-
ogists. Endoscopists and histopathologists had access to clinical 
information and calprotectin results but were blinded for the 
results of the calgranulin-C test. In case patients were assigned 
to the alternative reference standard, they were re-evaluated 
using the IBD Risk Stratifier until 6 months after inclusion. In 
case the initial risk stratum changed to ‘high-risk’, endoscopy 
was performed ultimately.
Figure 1 Algorithm explaining the multistep IBD Risk Stratifier used 
to standardise the assignment of patients to either endoscopy or clinical 
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statistical analysis
Statistical analysis was performed using the Statistical Package 
for the Social Sciences (SPSS, V.22.0 for Windows) and presented 
with GraphPad Prism (V.5 for Windows (San Diego, California, 
USA)). Diagnostic accuracy measures (sensitivity, specificity, 
positive predictive value and negative predictive value) were 
calculated for both the high-risk and low-risk stratum using 
predefined thresholds, as well as optimal thresholds (defined as 
the most upper left data point in the receiver operating charac-
teristic (ROC) curve). Since we used both endoscopy and clin-
ical follow-up as reference standard, with the latter being less 
accurate-, we used a Bayesian correction method to adjust for 
differential verification bias.15–17 This method takes into account 
the verification pattern as well as bias due to imperfection of 
the clinical follow-up in a single model. The method requires 
specifying the verification pattern and giving a best guess of the 
accuracy of both reference standards in the form of a prior distri-
bution. We assumed that endoscopy had 95%–100% sensitivity 
and 95%–100% specificity to diagnose IBD and that clinical 
follow-up had a sensitivity of 80%–100% and a specificity of 
60%–80% to diagnose latent IBD. Our inferences are based on 
the posterior distributions calculated using JAGS (‘Just Another 
Gibbs Sampler’), a free program licenced under GNU General 
Public License.18 The R-package script is provided in online 
supplementary data 1. The sample size calculation was previ-
ously described.12
human subjects protection
This study was performed according to the Declaration of 
Helsinki. This study was conducted with the approval of 
the Medical Ethical Committee of the University Medical 
Center in Groningen (METc 2013/503) and Antwerp Univer-
sity Hospital (14/40/407). All participants aged 12 years and 
above and their legal guardians gave informed consent to 
use data generated by routine medical care. The data were 
collected and recorded by the investigators in such a manner 
that subjects could not be identified, directly or through 
identifiers linked to the subjects.
resulTs
A total number of 354 children and teenagers with chronic 
abdominal pain and diarrhoea were recruited into the study 
between September 2014 and September 2016, and 337 were 
included in the final analysis. In the early stages, 142 patients 
proceeded to endoscopy, while 195 were assigned to clinical 
follow-up. Another 19 children from the low-risk group were 
referred for endoscopy at a later stage. Eventually, 48% of 
patients in the study cohort (161 of 337) underwent endoscopy, 
of which 93 were diagnosed with IBD. The patient study flow 
is shown in figure 2. Baseline characteristics are presented in 
table 1. The patients in the high-risk stratum were older, had 
more red flag symptoms and higher calprotectin concentrations 
than those in the low-risk stratum. Three patients who were 
initially in the low-risk stratum were later found to have IBD. 
All three had elevated faecal calprotectin concentrations (range 
340–480 µg/g) and a positive PCR result. Ongoing or worsening 
symptoms despite eradication of the pathogen made the clini-
cian decide to proceed to endoscopy. The distributions of calpro-
tectin and calgranulin-C values per final diagnosis are shown in 
figure 3.
Predefined thresholds
Figure 4A shows the diagnostic accuracy measures based on 
predefined thresholds for calprotectin (50 µg/g) and calgran-
ulin-C (0.75 µg/g), calculated with the Bayesian correction 
method. In this analysis, calgranulin-C has significantly better 
specificity (97.3% (95% credible interval (CI) 94.1% to 99.4%) 
vs 71.3% (95% CI 63.3% to 79.0%)) and better positive predic-
tive value (92.7% (95% CI 84.6% to 98.4%) vs 72.7% (95% CI 
63.8% to 81.0%) compared with calprotectin. The numerical 
data are shown in online supplementary file 2.
Optimal (rOC-based) thresholds
The optimal (ROC-based) threshold for calprotectin was 400 µg/g, 
while the optimal threshold of calgranulin-C was equal to the 
predefined threshold (0.75 µg/g). The difference in specificity and 
positive predictive value disappeared when optimal thresholds 
Figure 2 Study flow diagram showing differential verification bias. We 
compared calgranulin-C and calprotectin to see which of the two stool 
tests best predicted IBD in children with chronic abdominal pain and 
diarrhoea. Patients stratified by their paediatrician as high risk for IBD 
underwent endoscopy. Those with a low predicted risk were followed 
for 6 months. The probability that a patient truly had IBD given that they 
were in the high-risk stratum was 63%. Likewise, the probability that a 
patient in the low-risk stratum was eventually diagnosed with IBD was 
1.5%. IBD, inflammatory bowel disease; NPV, negative predictive value; 
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were compared. A graphical representation of the equivalence 
between calprotectin and calgranulin-C for the complete study 
cohort (verified with either reference test) is shown in figure 4B. 
ROC curves are presented in supplementary file 3.
Concordant versus discordant pairs
Figure 5 shows that 306 of 337 pairs of calprotectin and 
calgranulin-C results were concordant (91%). Discordant 
pairs (n=31 (9%)) are described in detail in supplementary 
file 4. Thirteen children with a discordant result were diag-
nosed with IBD. Two cases were missed with the calprotectin 
test (threshold 400 µg/g) and 11 cases were missed with the 
calgranulin-C test (threshold 0.75 µg/g).
DIsCussIOn
The clinical presentation of paediatric IBD is frequently 
non-specific and overlaps with irritable bowel syndrome (IBS). 
Early differentiation is important to avoid delay in proceeding 
to endoscopy on the one hand and to avoid unnecessary invasive 
procedures on the other. The mere existence of this trade-off 
means that a non-invasive and highly discriminative test is 
needed. We compared the calprotectin and calgranulin-C stool 
test to see which of the two markers best predicted IBD in chil-
dren and postulated that the latter probably had better speci-
ficity. In this large-scale paediatric diagnostic accuracy study on 
markers of intestinal inflammation, we show that calgranulin-C 
has better specificity for IBD than calprotectin, provided the use 
of common thresholds. When optimal (ROC-based) thresholds 
are used (ie, calprotectin: 400 µg/g; calgranulin-C: 0.75 µg/g), 
both tests have exceptionally high sensitivity and specificity to 
diagnose IBD.
Comparison with existing literature
Well-designed studies on the discriminative power of calgran-
ulin-C are scarce. An Australian research team previously 
reported on a study comparing calprotectin and calgranulin-C.9 
They obtained stool samples from 61 children (2–16 years old) 
who presented with gastrointestinal symptoms prior to admis-
sion for gastrointestinal endoscopy. The predefined threshold 
used for calgranulin-C in their study cohort (10 µg/g) was 
substantially higher than the one we used (0.75 µg/g).8 13 The 
difference is likely to be explained by differences in assays and 
selection of patients. We included a fair amount of patients that 
did not proceed to endoscopy, which increases the applicability 
of our results for populations seen in non-specialised centres. 
An important methodological flaw in the Australian study was 
the omission of a fair comparison of optimal thresholds for both 
markers, which may have resulted in an overinterpretation of 
calgranulin-C test accuracy. 
Several recently published meta-analyses have shown that the 
calprotectin stool test has good negative predictive (‘rule-out’) 
value at the commonly used threshold (50 µg/g).3 4 6 A large share 
of the studies included in these meta-analyses had a case–control 
design that gives rise to spectrum bias and overestimation of test 
accuracy relative to the real-life practice.19 We avoided spec-
trum bias and therefore expected to find more modest accuracy 
measures than previously reported. Contrary to our expecta-
tions, we found that the good rule-out value of calprotectin still 
holds in a heterogeneous study population with chronic abdom-
inal pain and diarrhoea.
At the threshold of 50 µg/g, the specificity of the calpro-
tectin test for the detection of IBD (71%) was comparable with 
previously reported values. The ROC-based optimal threshold 
was higher than in previously reported papers. We used the 
calprotectin ELISA assay of BÜHLMANN Laboratories, which 
is known to report higher concentrations than the Immunodi-
agnostik and Eurospittal assays.20 This so-called between-assay 
variability indicates the need for assay standardisation. In the 
meantime, each laboratory should investigate transferability of 
the manufacturer’s thresholds to its patient population and, 
if necessary, determine its own local thresholds to optimally 
identify IBD and avoid the need for further costly and invasive 
investigations.
strengths and limitations
This large-scale, multicentre, cross-border accuracy study better 
reflects ‘real-life’ practice than any other previously published 
study on stool tests for screening and selecting children for endos-
copy. We used an automated IBD Risk Stratifier to standardise 
the assignment of patients to either the high-risk or low-risk 
Table 1 Baseline characteristics of patients with chronic abdominal pain and diarrhoea stratified into high and and low risk for inflammatory 
bowel disease (IBD)
Characteristics high risk (n=142) low risk (n=195)
reference test endoscopy Clinical follow-up
Demographics
  Median age in years (IQR) 14 (11–15) 12 (9–14)
  Male gender 67 (47) 112 (57)
Major red flag symptoms
  Overt rectal blood loss 90 (63) 0 (0)
  Perianal disease (superficial anal fissures excluded) 20 (14) 0 (0)
Minor red flag symptoms
  Weight loss or linear growth deceleration 52 (37) 47 (24)
  Extraintestinal symptoms (including arthritis) 20 (14) 13 (7)
  Family history of IBD 12 (9) 18 (9)
  Anaemia (haemoglobin <−2 SD for age and gender) 56 (39) 19 (10)
Increased markers of inflammation (C reactive protein >10 mg/L or 
erythrocyte sedimentation rate >20 mm/hour)
58 (41) 10 (5)
Stool test
  Increased calprotectin (>50 µg/g) 125 (88) 76 (39)
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stratum. The cooperation of both secondary and tertiary level 
hospitals in this study promotes the generalisability of our results 
and conclusions.
The attending paediatricians were not blinded for the 
calprotectin results. This led to a deviation from the auto-
mated advice of the IBD Risk Stratifier in 25% of cases. In 
supplementary file 5, we show that this especially happened 
in the calprotectin grey zone between 50 µg/g and 400 µg/g. 
Knowledge of the calprotectin concentration also led to a 
diagnostic work-up bias that is usually the case in screening 
studies where only patients with a positive index test result 
move on to the reference standard. We reduced this bias by 
following the low-risk patients for 6 months for possible 
latent IBD to become visible. One might argue that this 
observation period was not sufficiently long, but we are 
confident that the majority of initially missed cases with IBD 
would become apparent within this time.
Clinical implications
Both calprotectin and calgranulin-C have excellent test char-
acteristics to predict IBD in children and teenagers with 
chronic abdominal pain and diarrhoea and justify endoscopy. 
In this inception cohort, the calprotectin action threshold for 
proceeding to endoscopy is around 400 µg/g, and this underlines 
the relevance of using a ‘two-threshold strategy’ as proposed in 
several publications.7 21–23 The grey zone between the commonly 
Figure 3 Box and whisker plot for calprotectin (A) and calgranulin-C 
(B) concentrations per diagnosis. Whiskers represent the 95% CI. 
Number of cases in brackets. *The GI infection group had either 
bacterial colon pathogens or Giardia lamblia. **The miscellaneous 
group included bile-salt diarrhoea (n=1), haemolytic uremic 
syndrome (n=1), Mediterranean fever (n=1), fructose overload (n=1), 
spondylarthropathy (n=1), Hirschsprung’s disease (n=1) and allergic 
enterocolitis (n=1). The remaining 12 were ‘non-IBD, not otherwise 
specified’. GI, gastrointestinal; IBD, inflammatory bowel disease; IBS, 
irritable bowel syndrome.
Figure 4 Diagnostic accuracy measures of the calprotectin (grey 
square) and calgranulin-C test (black diamond) to diagnose IBD in 
children. Graph A shows the results when predefined thresholds are 
used (50 µg/g and 0.75 µg/g, respectively). Graph B shows the results 
when ROC-based optimal thresholds (400 µg/g and 0.75 µg/g) are used. 
Whiskers represent the 95% credible interval. IBD, inflammatory bowel 
disease; NPV, negative predictive value; PPV, positive predictive value. 
Figure 5 Scatter plot showing concordant and discordant pairs 
of calprotectin and calgranulin-C measurements. The broken lines 
represent the ROC-based optimal thresholds for calprotectin (400 µg/g) 
and calgranulin-C (0.75 µg/g). White fields represent concordant pairs 
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used threshold of 50 µg/g that demarcates the normal range and 
the action threshold gives room for shared decision making 
with the patient and his or her parents, in which presence of 
major red flag symptoms and impact on daily functioning of 
the child may additionally guide management. One can opt for 
watchful waiting with monthly monitoring of stool calprotectin 
or decide to move on to endoscopic evaluation. When calpro-
tectin concentrations are truly out of range, and gastrointes-
tinal infections and non-steroidal anti-inflammatory drug use 
are excluded, the patient should proceed to endoscopy to rule 
in IBD. A two-threshold strategy does not seem to be of added 
value when the calgranulin-C stool test is picked as the triaging 
tool of preference.
Stool markers are of great help to distinguish IBD from IBS 
in children with only minor red flag symptoms. When chil-
dren present with major red flag symptoms of IBD, they will 
be referred for endoscopy regardless of the stool marker result. 
There is no added value of stool testing for triaging purposes 
in this category, although the knowledge of a baseline calpro-
tectin concentration is useful for monitoring the response to 
treatment. Physicians should take note that different patient 
populations and different test assays may lead to variations in 
thresholds.20 21 24
COnClusIOns
Measuring calprotectin or calgranulin-C concentrations in stool is 
a useful triage tool for identifying patients who are most likely to 
need endoscopy for suspected IBD. The discriminative power to 
safely exclude the disease (specificity) is significantly better than 
previously reported. When the optimal ROC-based thresholds are 
used (calprotectin: 400 µg/g; calgranulin-C: 0.75 µg/g), both tests 
perform equally well in secondary and tertiary level hospitals.
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